Last updated on November 2019

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ulcerative Colitis
  • Age: Between 16 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Subjects who have completed Study M16-065 or Study M16-067 and have achieved clinical response

Exclusion Criteria:

  • Subjects who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-065 or M16-067 that in the Investigator's judgment makes the subject unsuitable for this study
  • Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
  • Subject is not in compliance with prior and concomitant medication requirements throughout Studies M16-065 and M16-067

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.